Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | USP1 | O94782 | 1/20 | 0.31 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.31 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.31 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1178300 | 0.94 | PTPN1 (0.36) | MAOBPARP1PTGESITGB3ITGA2B | |
| SCHEMBL1081126 | 0.92 | PTGES (0.40) | MAOBPARP1PTGESITGB3ITGA2B | |
| SCHEMBL1178374 | 0.90 | MAOB (0.32) | MAOB | |
| SCHEMBL1178399 | 0.88 | MAOB (0.33) | MAOBPARP1ITGB3ITGA2BACKR3 | |
| SCHEMBL1178359 | 0.87 | PTGES (0.39) | PTGES | |
| SCHEMBL1177863 | 0.87 | PTGES (0.33) | MAOBPTGES | |
| SCHEMBL1063556 | 0.86 | MAOB (0.39) | MAOBITGB3ITGA2B | |
| SCHEMBL3693615 | 0.86 | ITGB3 (0.36) | MAOBPARP1ITGB3ITGA2BACKR3 | |
| SCHEMBL3698389 | 0.86 | ITGB3 (0.35) | MAOBPARP1ITGB3ITGA2BACKR3 | |
| SCHEMBL1179010 | 0.86 | MAOB (0.35) | MAOBPARP1ITGB3ITGA2BACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987256-B2 | Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| EP-2268625-B1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | Bayer Pharma AG (DE) | 2012-05-16 | — | — | EP | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | OTC, PC, HCAR2 | MAOB 147/4885PARP1 1838/4885PTGES 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.